Renovaro And Amsterdam University Medical Center Collaborates For Blood Platelet RNA Diagnostics Breakthrough

Renovaro Inc., a leader in TechBio specializing in next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, has announced a new exclusive collaboration agreement with Amsterdam University Medical Center. The partnership will focus on jointly evaluating and developing blood platelet RNA diagnostics, marking a significant advancement in the clinical validation and progression of this promising new approach to disease detection and monitoring.

The collaboration will center on assessing the clinical utility of blood platelet RNA signatures as a powerful source of biomarkers. Renovaro’s advanced Artificial Intelligence (AI) and Machine Learning (ML) technologies, combined with new computational resources from their agreement with Nebul, will be leveraged to detect subtle disease-specific signals from blood samples. This effort aims to transform diagnostic and prognostic methods across various cancer types.

David Weinstein, CEO of Renovaro, said in a statement, “We are excited to partner with Amsterdam UMC, a leader in translational research, to advance this promising technology. By combining their clinical expertise with our technological capabilities, we believe we can significantly accelerate the translation of blood platelet RNA diagnostics into clinical practice.”

Under the terms of the agreement, both Renovaro and Amsterdam UMC will work together to refine and enhance the predictive performance of this diagnostic approach, with the goal of achieving high clinical accuracy. The project will involve the collection and analysis of blood samples, data integration from multiple sources, and the development of advanced deep learning models.

Both organizations have agreed to jointly manage the intellectual property resulting from the collaboration. They also plan to establish a dedicated company in the Netherlands to continue the development and commercialization of the resulting diagnostics. The initial term of the collaboration is set for four years, with the option to extend it by mutual agreement.